Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Milios

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Systematic Reviews|January 4, 2022
Mapping the prevalence and use of questionnaires to detect the neglected sexual side effects after prostate cancer treatment: a scoping reviewPierre Röscher, Ronisha Sathiram, Joanne E Milios, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 1, 1991
Substance P-like immunoreactivity and somatostatin-like immunoreactivity in the ventricular fluid of patients with chronic pain syndromesS Jost, C Reuner, J Geiger, et al.
Neuropeptides|February 1, 1991
Ventricular fluid neuropeptides in Parkinson's disease. II. Levels of substance P-like immunoreactivityH Cramer, S Jost, C Reuner, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Systematic Reviews|January 4, 2022
Mapping the prevalence and use of questionnaires to detect the neglected sexual side effects after prostate cancer treatment: a scoping reviewPierre Röscher, Ronisha Sathiram, Joanne E Milios, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 1, 1991
Substance P-like immunoreactivity and somatostatin-like immunoreactivity in the ventricular fluid of patients with chronic pain syndromesS Jost, C Reuner, J Geiger, et al.
Neuropeptides|February 1, 1991
Ventricular fluid neuropeptides in Parkinson's disease. II. Levels of substance P-like immunoreactivityH Cramer, S Jost, C Reuner, et al.
Pageof 2